Printer Friendly

OGEN RECEIVES ADDITIONAL INDICATION FOR OSTEOPOROSIS PREVENTION

 OGEN RECEIVES ADDITIONAL INDICATION FOR OSTEOPOROSIS PREVENTION
 ABBOTT PARK, Ill., Nov. 12 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) announced today that its estrogen replacement therapy, Ogen (estropipate), cleared U.S. Food and Drug Administration review for a supplemental indication for the prevention of postmenopausal osteoporosis.
 "Receiving approval for this indication will allow Ogen to compete in the osteoporosis segment of the estrogen replacement market," said Paul N. Clark, senior vice president, pharmaceutical operations.
 Osteoporosis is a condition that affects nearly 20 million Americans, primarily postmenopausal women. The condition is characterized by a decrease in bone mass that can lead to an increase in bone fractures. This is particularly true in the hips and spine.
 "Estrogen has a protective effect on bone by slowing or halting bone loss," said Christopher Gallagher, M.D., professor of medicine at Creighton University Medical School. "Results from a double-blind, placebo-controlled study show the .625 dose of Ogen, given with supplemental calcium, is effective for the prevention of spinal bone loss. Calcium alone was ineffective."
 A woman may lose as much as 15 to 20 percent of her bone mass in the first 10 to 15 years following menopause. Estrogen replacement therapies slow the bone-thinning effects of estrogen loss and reduce the risk of osteoporosis and bone fractures.
 Ogen has been prescribed primarily for the treatment of estrogen deficiency associated with moderate to severe vasomotor symptoms of menopause (hot flushes).
 In 1991, total sales for all estrogen replacement therapies in the United States were almost $600 million.
 Abbott Laboratories is a worldwide manufacturer of health care products employing 47,000 people. In 1991, the company's sales and net earnings were $6.9 billion and $1.1 billion respectively, with earnings per share of $2.55.
 -0- 11/12/92
 /CONTACT: Matt Kuhn of Abbott Laboratories, 708-937-2993/
 (ABT) CO: Abbott Laboratories ST: Illinois IN: MTC SU:


WB -- NY026 -- 0110 11/12/92 10:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 12, 1992
Words:317
Previous Article:MCI SECOND LARGEST U.S. PARTNER IN COLUMBUS II OPTICAL FIBER CABLE SYSTEM
Next Article:MICHIGAN STATE UNIVERSITY GENERAL REVENUE BONDS RATED 'AA-' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
WATSON PHARMACEUTICALS RECEIVES FDA APPROVAL FOR TWO OFF-PATENT DRUGS
UPJOHN ACQUIRES RIGHTS TO MARKET ESTROGEN REPLACEMENT DRUG OGEN FROM ABBOTT
NATIONAL OSTEOPOROSIS FOUNDATION'S PREVENTION WEEK BEGINS MOTHER'S DAY, MAY 8; BRISTOL-MYERS SQUIBB AND NOF OFFER FREE INFORMATION
JOURNALISTS PRESENTED WITH INTERNATIONAL AWARD ON WORLD OSTEOPOROSIS DAY.
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis.
Biyearly zoledronic acid gets nod for bone loss prevention.
Amgen to discusses Denosumab data at Advisory Committee for Reproductive Health Drugs.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters